Short answer: In the groups studied, yes — semaglutide has shown both heart and kidney benefits in large trials. But the benefits were proven in specific populations, and “protects” doesn’t mean “guarantees.” Knowing who the evidence applies to is the key.
The kidney evidence. In the FLOW trial, adults with type 2 diabetes and chronic kidney disease who took semaglutide 1.0 mg had about a 24% lower risk of major kidney events (like kidney failure or a large drop in kidney function) versus placebo (hazard ratio 0.76) — a hard-endpoint benefit.
The heart evidence.
- In people with type 2 diabetes, semaglutide reduced major cardiovascular events in earlier trials.
- In the SELECT trial (17,604 adults with obesity and established cardiovascular disease but without diabetes), major cardiovascular events occurred in 6.5% on semaglutide vs 8.0% on placebo — about a 20% lower risk (hazard ratio 0.80; an absolute difference of ~1.5 percentage points). That extended the heart benefit beyond diabetes.
Why “heart and kidney together” makes sense. The heart, kidneys, and metabolism are deeply linked — the same drivers (excess weight, high blood pressure, high blood sugar, inflammation) damage all three. A treatment that improves those drivers can help across the whole system. This is the idea behind the cardiovascular-kidney-metabolic (CKM) framework.
The important limits.
- Populations matter. The kidney-outcome proof is in diabetes + CKD. The heart proof spans diabetes and (in SELECT) obesity with heart disease. If you don’t fit those groups, the benefit is less certain, even if plausible.
- “Protect” is relative. These drugs lower risk; they don’t remove it. Other proven therapies (blood-pressure control, SGLT2 inhibitors, statins where appropriate) remain part of the plan.
- It’s not automatic for everyone. Whether semaglutide is right for your heart and kidneys is a personal decision with your clinician.
Bottom line. Semaglutide is one of the few treatments with proven benefits for both the heart and the kidney — in the specific groups studied. That’s a genuine strength, as long as it’s understood for whom, and alongside the other proven pieces of care.
Full guide: Semaglutide (Ozempic/Wegovy) and Your Kidneys.
Related questions
Does Ozempic help the heart if I don’t have diabetes? In the SELECT trial, semaglutide reduced cardiovascular events in people with obesity and heart disease without diabetes. The kidney-outcome proof, however, comes from people with diabetes and CKD.
Is the kidney benefit separate from the heart benefit? They overlap. The heart, kidney, and metabolism share the same risk drivers, so improving them tends to help across the board — but the strongest kidney proof is specifically in diabetes + CKD.
Do I still need my other heart and kidney medicines? Usually yes. Semaglutide adds to — rather than replaces — proven therapies like blood-pressure control and, where appropriate, SGLT2 inhibitors and statins.
📬 Get two free guides + stay current. Join the newsletter and instantly get our two free PDF guides — Sick-Day Rules for Weight-Loss Injections and 5 Questions to Ask Before Starting a Weight-Loss Injection — plus a short monthly email when a new study actually changes how we think about weight-loss medication and your kidneys. No hype, no selling.
Written and medically reviewed by Dr. Amir S. Naderi, MD, FASN. Last updated: July 8, 2026. Educational information only — not medical advice. Never change or stop a prescribed medication without talking to your doctor.